丽珠集团 (000513.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

26.5x

EV/EBITDA

5.3x

Market Cap

CNY 23.39B

MomentumView details →

1D Return

−9.98%

YTD Return

−22.32%

RSI (14)

35.4

ValuationView details →

P/E (Fwd)

26.5x

EV/EBITDA

5.3x

Market Cap

CNY 23.39B

RSI (14)

35.4

MomentumView details →

1D Return

−9.98%

YTD Return

−22.32%

ProfitabilityView details →

Gross Margin

66.14%

Net Margin

16.77%

EBITDA Margin

30.31%

ROE (TTM)

13.53%

ROA (TTM)

8.12%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

−0.33%

EPS YoY

−3.91%

FCF YoY

+21.91%

Revenue CAGR 3Y

−1.63%

EPS CAGR 3Y

+3.63%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.40

EPS Surprise

−37.51%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.51

Avg Surprise (4Q)

−37.51%

Rev Surprise

−28.61%

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

1.96x

Quick Ratio

1.77x

Div Yield

5.34%

Div Rate

CNY 1.43

Div Growth 1Y

+30.00%

Financials snapshotView financials →

Revenue (TTM)

11.71B

Net Income (TTM)

1.96B

Op. CF (TTM)

3.24B

Next earningsOct 27, 2026 →

Latest newsMore news →

Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.8d ago

Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.12d ago

Similar companies

航发控制000738.SZ 华兰生物002007.SZ 尚太科技001301.SZ 广电运通002152.SZ 托伦斯301583.SZ 晶澳科技002459.SZ Find similar companies →

Latest newsMore news →

Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.8d ago Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.12d ago